Blog›Comparisons
Comparisons·14 min read·Published Jun 28, 2026·Updated Oct 18, 2026

Mounjaro vs Ozempic 2026: A1C, Weight & Cost

Mounjaro vs Ozempic for type 2 diabetes: SURPASS-2 A1C and weight results, heart and kidney approvals, the Ozempic pill, and 2026 self-pay prices.

Nouri Editorial Team

Facts checked Oct 13, 2026 against the primary sources linked below

Quick answer: Mounjaro (tirzepatide, Eli Lilly) and Ozempic (semaglutide, Novo Nordisk) are weekly injections FDA-approved for type 2 diabetes. In SURPASS-2, the only trial that compared them directly, Mounjaro lowered A1C by up to 2.3 points over 40 weeks versus 1.9 on Ozempic 1 mg, and body weight by up to 11.2 kg versus 5.7 kg. Both now carry a heart-risk approval; only Ozempic is approved to slow kidney disease in type 2 diabetes, and only Ozempic also comes as a daily tablet. Self-pay, the Mounjaro pen is $499 a month at every dose through LillyDirect; NovoCare charges $349 for Ozempic up to 1 mg and $499 at 2 mg. Neither is approved for weight loss; those versions are Zepbound and Wegovy.

Mounjaro and Ozempic are brand-name prescription medicines for adults with type 2 diabetes. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist; Ozempic contains semaglutide, a GLP-1 receptor agonist. Each maker also sells its molecule for weight loss under a second name, so this page stays on the diabetes labels: blood sugar, heart and kidney outcomes, dosing and what each costs in 2026. Here for weight loss? The like-for-like comparison is Zepbound vs Wegovy; for the molecules themselves, see tirzepatide vs semaglutide in 2026.

  • SURPASS-2 (1,879 adults with type 2 diabetes on metformin, 40 weeks): A1C fell 2.0 to 2.3 points on Mounjaro 5 to 15 mg versus 1.9 on Ozempic 1 mg; 86% versus 79% reached an A1C under 7%.
  • Organ protection: Ozempic is approved to lower heart attack, stroke and kidney-decline risk in type 2 diabetes; Mounjaro gained a heart-risk approval in August 2026 after SURPASS-CVOT.
  • Self-pay: Mounjaro pen $499 a month at any dose (LillyDirect); Ozempic pen $349 up to 1 mg and $499 at 2 mg, Ozempic tablets $149 to $299 (NovoCare).

At a glance: Mounjaro vs Ozempic

From the current FDA labels and makers' pages, checked Oct 13, 2026: Mounjaro label (DailyMed), Ozempic injection label (DailyMed), Ozempic tablets label (DailyMed), LillyDirect, NovoCare price guide.
Mounjarotirzepatide · Eli LillyOzempicsemaglutide · Novo Nordisk
FormsSingle-dose pen, single-dose vial, multi-dose vial and KwikPen (the last two hold 4 weekly doses)Multi-dose pen (four weekly doses per pen) and single-dose syringes; Ozempic tablets 1.5, 4 and 9 mg
How you take itOnce a week, any time of day, with or without mealsPen once a week, any time of day. Tablet every morning before eating, with a sip of water (4 oz at most) and a half-hour wait
FDA-approved forBlood-sugar control in adults and children 10 and older with type 2 diabetes; lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk (added Aug 2026)Blood-sugar control in adults with type 2 diabetes; cutting major heart events where heart disease is established; slowing kidney failure and kidney-related death where chronic kidney disease is present (added Jan 2025) (label)
Dose steps2.5 mg for 4 weeks, then up 2.5 mg at a time, at least 4 weeks apart, if more glucose control is neededStarts at 0.25 mg for a month, then 0.5 mg; 1 mg and later 2 mg are added only if A1C needs it. Tablets: 1.5 mg for 30 days, 4 mg, then 9 mg
Maximum dose15 mg weekly (10 mg in children)2 mg weekly; tablets 9 mg daily
Self-pay from$499 a month at any dose (pen)$199 for each of the first two pen fills (new patients), then $349; tablets from $149
Same molecule, weight-loss labelZepboundWegovy

Mounjaro vs Ozempic results: the SURPASS-2 head-to-head

SURPASS-2 gave 1,879 adults with type 2 diabetes, already on metformin, either Mounjaro (5, 10 or 15 mg) or Ozempic 1 mg for 40 weeks. The first three rows come from it. Ozempic 2 mg was approved later and has only been tested against Ozempic 1 mg, in a separate trial (last row).

Results from each drug's trials. Every row counts people the same way across the columns; the trial, its size and its length sit under each number.
ResultMounjarotirzepatide · Eli LillyOzempicsemaglutide · Novo Nordisk
A1C reduction at 40 weeks (percentage points)Counting: all who took a dose, counting those who quit or added rescue drugs (treatment-regimen)2.3 pointsSURPASS-2, 1,879 people, 40 weeks; 15 mg; 2.0 at 5 mg, 2.2 at 10 mg1.9 pointsSURPASS-2, 1,879 people, 40 weeks; 1 mg
Reached an A1C below 7%Counting: all who took a dose, counting those who quit or added rescue drugs (treatment-regimen)86%SURPASS-2, 1,879 people, 40 weeks; 15 mg, per the Mounjaro label79%SURPASS-2, 1,879 people, 40 weeks; 1 mg, per the Mounjaro label
Weight change at 40 weeks (a secondary outcome)Counting: all who took a dose, counting those who quit or added rescue drugs (treatment-regimen)11.2 kgSURPASS-2, 1,879 people, 40 weeks; 15 mg, from about 94 kg; 7.6 kg at 5 mg5.7 kgSURPASS-2, 1,879 people, 40 weeks; 1 mg, from about 94 kg
A1C reduction, Ozempic 2 mg vs 1 mgCounting: everyone randomized (intent-to-treat), with missing values imputed from people who stoppedNot studied2.1 pointsSUSTAIN FORTE (Ozempic label), 961 people, 40 weeks; 2 mg; 1.9 at 1 mg

A1C figures are percentage points from a starting average of 8.3% (SURPASS-2) or 8.8–8.9% (SUSTAIN FORTE). The NEJM paper gives the SURPASS-2 A1C results as 2.01, 2.24 and 2.30 versus 1.86; an on-treatment analysis posted on ClinicalTrials.gov, which drops data after people stopped, shows larger drops for both drugs. SURPASS-2 was open-label and funded by Eli Lilly. These results describe the branded medicines only.

Heart and kidney protection: SUSTAIN 6, SURPASS-CVOT and FLOW

Both drugs now carry a cardiovascular approval for people with type 2 diabetes, but the trials behind them were built differently:

  • Ozempic, SUSTAIN 6: 3,297 adults with type 2 diabetes and heart disease or high risk, against placebo. Over a median 2.1 years, 6.6% on Ozempic versus 8.9% on placebo had a heart attack, stroke or cardiovascular death (hazard ratio 0.74) (Marso et al., NEJM 2016).
  • Mounjaro, SURPASS-CVOT: 13,299 adults with type 2 diabetes and established heart disease, against another GLP-1 drug, dulaglutide (Trulicity) 1.5 mg, not placebo. Over a median of about four years, 12.1% versus 13.0% had one of those events (hazard ratio 0.92), which met the trial's test for being no worse than dulaglutide. The heart-risk indication was added to Mounjaro's label in August 2026 (Mounjaro label).
  • Ozempic, FLOW: 3,533 adults with type 2 diabetes and chronic kidney disease, against placebo. Over a median 3.4 years, 18.7% on Ozempic 1 mg versus 23.2% on placebo had a major kidney decline, kidney failure, or died of kidney or cardiovascular causes, a 24% lower risk (Perkovic et al., NEJM 2024). Mounjaro has no kidney-outcome approval.

Because SUSTAIN 6 used placebo and SURPASS-CVOT used an active drug, their hazard ratios cannot be set against each other.

Mounjaro or Ozempic for weight: what the diabetes labels cover

Neither Mounjaro nor Ozempic is FDA-approved for weight loss. Weight was a secondary outcome in SURPASS-2, where it fell more on Mounjaro (see the table), and people with type 2 diabetes generally lose less on these drugs than people without it. Some prescribers use either one off-label for weight; that decision, and whether a plan will pay, rests with the prescriber and the insurer, and diabetes-drug coverage usually requires the diagnosis.

The same molecules carry weight-loss labels under other names. In their own trials in adults without diabetes, tirzepatide 15 mg (Zepbound) averaged 20.9% weight loss at 72 weeks (SURMOUNT-1) and Wegovy (semaglutide 2.4 mg) 14.9% at 68 weeks (STEP 1); head to head in SURMOUNT-5, 20.2% versus 13.7%. Wegovy's heart approval rests on a separate trial, SELECT, in people without diabetes. Background from the NIDDK overview of prescription medications for obesity. More on tirzepatide vs semaglutide, which GLP-1 is most effective for weight loss, Zepbound vs Ozempic, and Ozempic vs Wegovy (how the two semaglutide labels differ).

Mounjaro or Ozempic: who each one fits

What the FDA labels and trials point to. A licensed prescriber makes the call.
If you…What the labels and trials point to
Want the larger A1C drop seen head-to-headMounjaro: 2.0 to 2.3 points versus 1.9 on Ozempic 1 mg in SURPASS-2 (Ozempic 2 mg was not in that trial)
Have diabetic kidney diseaseOzempic is the one approved to lower the risk of kidney decline (FLOW)
Have established heart diseaseBoth carry a heart-risk indication: Ozempic from a placebo-controlled trial (SUSTAIN 6), Mounjaro from a trial against dulaglutide (SURPASS-CVOT)
Are 10 to 17 with type 2 diabetesMounjaro is approved from age 10 (up to 10 mg); Ozempic is approved for adults
Would rather take a pillOzempic tablets (daily, before breakfast); there is no Mounjaro pill
Also take insulin or a sulfonylureaBoth labels warn of low blood sugar in combination; the dose of those drugs may need lowering
Rely on the contraceptive pillMounjaro's label says to switch to a non-oral method, or add a barrier one, for 4 weeks after the first dose and after every increase; Ozempic's label says nothing similar
Want to lose weight and don't have diabetesNeither is approved for that; the weight-labelled versions are Zepbound and Wegovy (Zepbound vs Wegovy). For the wider field: which GLP-1 is most effective for weight loss

Your plan's formulary often settles it: many plans prefer one brand for type 2 diabetes and require the other to be tried first.

How do side effects compare?

Both act on the GLP-1 receptor, so the common side effects are the same kind: stomach and gut effects that peak after each dose increase. In SURPASS-2, the rates were close:

SURPASS-2, adults with type 2 diabetes, 40 weeks; Mounjaro figures span the 5, 10 and 15 mg groups (NEJM 2021).
Side effectMounjarotirzepatide · Eli LillyOzempicsemaglutide · Novo Nordisk
Nausea17–22%18%
Diarrhea13–16%12%
Vomiting6–10%8%
Low blood sugar (below 54 mg/dL)0.2–1.7%0.4%
Serious adverse events5–7%3%

Both labels list nausea, vomiting, diarrhea, and constipation as the most common effects. Each has a boxed warning on thyroid C-cell tumors in rodents and is contraindicated where there is medullary thyroid carcinoma in the person or family, or MEN 2. Rarer but serious: pancreatitis and gallbladder disease, kidney injury from dehydration, severe stomach reactions, allergic reactions, worsening diabetic eye disease in people with a history of retinopathy, and aspiration risk under anesthesia. Sources: Mounjaro label, Ozempic label, and the 2025 PDFs from the FDA (Mounjaro, Ozempic). Tirzepatide's GI side effects in more depth, and which GLP-1 has the fewest side effects.

How much do Mounjaro and Ozempic cost without insurance?

Both makers publish self-pay prices. Mounjaro costs the same at every dose; the Ozempic pen is cheaper up to 1 mg and matches Mounjaro at 2 mg:

Manufacturer self-pay prices, medication only, checked Oct 13, 2026. The first-year column is our arithmetic, explained below the table.
OptionMonth 1Usual maintenance monthFirst-year estimateSource
Mounjaro single-dose pen (LillyDirect)$499 (2.5 mg)$499 at every dose (listed as "starting at")$5,988LillyDirect Mounjaro
Ozempic pen, 0.25 mg up to 1 mg$199 (new-patient offer, first two fills of 0.25 or 0.5 mg)$349 at 0.25–1 mg$3,888NovoCare price guide
Ozempic pen, reaching 2 mg$199 (new-patient offer)$499 at 2 mg$5,238NovoCare price guide
Ozempic tablets$149 (1.5 mg)$199 at 4 mg; $299 at 9 mg$3,338NovoCare price guide

First-year estimates are our arithmetic: 12 monthly fills at each maker's listed self-pay price, for the medicine alone (no prescriber fee). Mounjaro: 12 fills at $499. Ozempic pen to 1 mg: the two $199 offer fills (0.25 and 0.5 mg), then 10 at $349. Ozempic pen to 2 mg: the two offer fills, one month on 1 mg, then 9 at $499. Ozempic tablets: 1.5 mg, 4 mg, then 10 fills at 9 mg (staying on 4 mg instead: $2,338). Each pen fill covers 28 days, so a full year needs a 13th. The $199 offer runs through Dec 31, 2026.

With insurance: both are type 2 diabetes drugs, and plans cover them for that use far more often than they cover weight-loss drugs; what you pay depends on your plan. Lilly's Mounjaro savings card lets commercially insured patients whose plan covers it pay "as little as $25" for up to a 3-month fill, with savings capped at $150 a month and $1,950 a year; if the plan does not cover Mounjaro, the card brings a fill to $499 (Mounjaro savings terms). Novo's Ozempic card offers "as little as $25" a month "for up to 3 months" to covered commercial patients, with up to $100 a month in savings (NovoCare offer terms). Government plans such as Medicare and Medicaid can't be combined with either card. More: Ozempic's out-of-pocket cost in detail, the GLP-1 cost guide for 2026, and Compare published GLP-1 prices.

Switching between Mounjaro and Ozempic

The two do not convert milligram for milligram, and neither label gives a switching schedule. Moving from Ozempic to Mounjaro means a new prescription that starts at Mounjaro's 2.5 mg dose for 4 weeks; moving the other way starts Ozempic at 0.25 mg. Ozempic injections and Ozempic tablets don't convert milligram for milligram either; the tablet label has its own switching table. Your prescriber sets the timing and watches blood sugar, especially alongside insulin or a sulfonylurea. Step by step: switching from semaglutide to tirzepatide.

Where does compounded tirzepatide or semaglutide fit?

Telehealth companies also sell compounded tirzepatide and compounded semaglutide, mixed by state-licensed 503A compounding pharmacies, often to people for whom brand-name GLP-1 medications are inaccessible because of cost or coverage. These copies are not FDA-approved: the agency has not checked them for safety, effectiveness or quality, they are distinct products from Mounjaro and Ozempic, and none is labelled for diabetes care. None of the SURPASS or SUSTAIN results above carry over to them. Read the FDA overview of human drug compounding and its GLP-1 compounding safety guidance. Prices side by side: compounded vs brand GLP-1 cost; tirzepatide price without insurance and semaglutide cost per month.

Related comparisons

Frequently asked questions

Is Mounjaro the same as Ozempic?

No: Mounjaro is tirzepatide from Eli Lilly, which acts on GIP and GLP-1 receptors, while Ozempic is Novo Nordisk's semaglutide, which acts on GLP-1 receptors only. Both are weekly injections approved for type 2 diabetes, with different dose scales and labels.

Which causes more weight loss, Mounjaro or Ozempic?

In SURPASS-2, adults with type 2 diabetes lost an average of up to 11.2 kg on Mounjaro 15 mg compared with 5.7 kg on Ozempic 1 mg over 40 weeks. Weight was a secondary outcome, and neither brand is approved for weight loss.

Are Mounjaro and Zepbound the same drug?

Both contain tirzepatide from Eli Lilly: Mounjaro is labelled for type 2 diabetes and Zepbound for weight reduction and sleep apnea. The approved uses, pens and prices differ.

Is Mounjaro stronger than Ozempic?

In the head-to-head SURPASS-2 trial, every Mounjaro dose lowered A1C more than Ozempic 1 mg (2.0 to 2.3 points versus 1.9) and lowered weight more. Ozempic 2 mg was not part of that trial.

What is the difference between Mounjaro and Wegovy?

Mounjaro is tirzepatide for type 2 diabetes; Wegovy is semaglutide for weight management, heart-risk reduction and MASH liver disease. Mounjaro's weight-loss counterpart is Zepbound, and Wegovy's diabetes counterpart is Ozempic.

Can I get tirzepatide or semaglutide without the brand-name product?

Telehealth companies sell compounded tirzepatide and semaglutide made by state-licensed pharmacies, but these are not FDA-approved and are separate products from Mounjaro, Ozempic, Zepbound or Wegovy. The brand-name trial results do not apply to them.

Which lowers A1C more, Mounjaro or Ozempic?

Mounjaro did in SURPASS-2: A1C fell 2.0, 2.2 and 2.3 points on 5, 10 and 15 mg versus 1.9 points on Ozempic 1 mg, from a starting average of 8.3%.

How much do Mounjaro and Ozempic cost without insurance?

Through LillyDirect, the Mounjaro pen is $499 a month at every dose. NovoCare lists Ozempic at $349 a month up to 1 mg and $499 at 2 mg, with Ozempic tablets from $149 (prices checked Oct 13, 2026).

Is there an Ozempic pill?

Yes: Ozempic tablets (1.5, 4 and 9 mg, taken once daily before breakfast) are approved for type 2 diabetes and share a label with Rybelsus. There is no Mounjaro pill.

Is Mounjaro approved to lower heart risk?

Yes, since August 2026 the Mounjaro label includes lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk, based on the SURPASS-CVOT trial against dulaglutide.

Sources and references

  1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM 2021;385:503-515 (accessed Oct 13, 2026)
  2. ClinicalTrials.gov NCT03987919 (SURPASS-2 posted results) (accessed Oct 13, 2026)
  3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). NEJM 2016;375:1834-1844 (accessed Oct 13, 2026)
  4. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). NEJM 2024;391:109-121 (accessed Oct 13, 2026)
  5. DailyMed: Mounjaro label, revised Aug 2026 (includes SURPASS-CVOT) (accessed Oct 13, 2026)
  6. DailyMed: Ozempic injection label, Jun 2026 (includes SUSTAIN FORTE) (accessed Oct 13, 2026)
  7. DailyMed: Rybelsus / Ozempic tablets label (accessed Oct 13, 2026)
  8. SURMOUNT-1 (tirzepatide in obesity), NEJM 2022 (accessed Oct 13, 2026)
  9. STEP 1 (semaglutide 2.4 mg in obesity), NEJM 2021 (accessed Oct 13, 2026)
  10. SURMOUNT-5 (tirzepatide vs semaglutide in obesity), NEJM 2025 (accessed Oct 13, 2026)
  11. SELECT (semaglutide and heart outcomes without diabetes), NEJM 2023 (accessed Oct 13, 2026)
  12. Lilly: Mounjaro on LillyDirect (accessed Oct 13, 2026)
  13. Lilly: Mounjaro savings card and terms (accessed Oct 13, 2026)
  14. Novo Nordisk: Ozempic pill and pen price guide, May 2026 (NovoCare) (accessed Oct 13, 2026)
  15. Novo Nordisk: Ozempic savings offer (NovoCare) (accessed Oct 13, 2026)

This page compares published trials, FDA labels and makers' price pages; it is not medical advice, and a licensed prescriber decides which drug and dose fit you. Trial results are for the FDA-approved branded drugs only. Nouri is a publisher; it does not prescribe or sell any medication, and it is not affiliated with Eli Lilly or Novo Nordisk. Facts checked Oct 13, 2026; prices change, so confirm at the source.

Disclosure: Nouri may earn a commission when you sign up with some of the providers we link to. It doesn't change what you pay or how we rank providers. This comparison has no partner link in its text, and no drug maker paid for it. Full disclosure.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.

Before you choose

Compare licensed GLP-1 providers

Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.

← Back to all articles